Navigation Links
Regado Biosciences Awarded Three Grants from the Federal Government to Advance Research of Lead Programs
Date:11/3/2010

This technology is being applied to injectable antithrombotics (including anticoagulants and antiplatelet agents) in the acute and sub-acute care cardiovascular setting, a multi-billion dollar world-wide market in need of drugs with improved safety profiles and a greater degree of therapeutic control.  The products in Regado's pipeline are designed to act as optimized antithrombotics, uniquely concomitantly minimizing the risk of ischemia and bleeding, and, by allowing patient specific tuning of the desired therapeutic effect, providing a safe and unique approach to personalized medicine.

ABOUT REG1, REG2 and REG3  Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (pegnivacogin, a.k.a. RB006) and the second being its complementary active control agent (anivamersen, a.k.a. RB007).  Anivamersen can be used to selectively completely or partially reverse the anticoagulant effect of pegnivacogin.  REG1, presently in a phase 2b clinical trial (the RADAR trial), is intended for application in arterial thrombosis applications, initially in Acute Coronary Syndrome patients intended for Percutaneous Coronary Intervention.  A clinical program in Open Heart Surgery [including coronary artery bypass grafting (CABG) and valve repair/replacement] is also under development.  REG2, Regado's second product candidate, consists of a subcutaneously administered depot formulation of pegnivacogin paired with the IV bolus formulation of anivamersen.  REG2 recently completed single escalating dose phase 1 clinical testing (the first successful subcutaneous application of an aptamer in humans) and is planned to be studied in a multiple escalating dose clinical trial in 2011.  It is intended for use in venous thrombosis indications such as venous thromboembolism (VTE) prophylaxis in patients undergoing abdominal s
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Regado Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference in New York City
2. Regado Biosciences to Present at the UBS Global Life Sciences Conference on September 22, 2010 in New York City
3. Regado Biosciences, Inc. Continues to Expand Its Patent Portfolio By Announcing Issuance of a New Patent for Its Product Candidates, the REG1 and REG2 Anticoagulation Systems
4. Regado Biosciences to Present at the BIO International Convention Held in Chicago, Illinois on May 5, 2010
5. Regado Biosciences to Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17, 2009
6. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 16, 2009
7. Regado Biosciences To Present at the 2009 Japan Biopharma Partnering Conference on October 6, 2009
8. Regado Biosciences Announces Allowance in Europe of a Fundamental Patent Broadly Covering Oligonucleotide Modulators to Blood Coagulation Factor Aptamers
9. Regado Biosciences to Present at the BioPharm America 2009 Conference on September 17, 2009
10. Regado Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2009 on September 11, 2009
11. Regado Biosciences to Present at the Rodman & Renshaw Global Investment Conference on September 10, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 27, 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... regenerative medicine, today announced that executives from the company ... of September.  , Pedro Lichtinger ... Renshaw,s 17th Annual Global Investment Conference on Wednesday, September ... Regis Hotel in New York City ...
(Date:8/27/2015)... , Aug. 27, 2015 HUYA Bioscience ... meeting of the Japan Society of HTLV-1, held this ... Auditorium. The purpose of the Society is to promote ... the development of medical technology and research related to ... welfare. "HUYA is proud to support this ...
(Date:8/27/2015)... ... August 27, 2015 , ... Inc. Magazine released its ... iLab Solutions as number 1,361 in growth for the three years through 2014. Being ... 0.1% fastest-growing privately held organizations in the country. , “We are thrilled to ...
(Date:8/27/2015)... 27, 2015 In response to recent ... and The US Postal Service to no longer ... ,select agents, by the CDC, Marken reaffirmed today ... sensitive shipments. Marken uses its flexible ... and certified personnel to ensure the safe and ...
Breaking Biology Technology:Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3Marken Ensures Safe Transportation Of Select Agents And Toxins 2
... Highest in Company History; Full Year Revenue Up 13% ... Over Prior Year Company Provides FY09 Outlook ... VIEW, Calif., May 8 Pharsight,Corporation (Nasdaq: PHST ... to optimize clinical drug development, today announced,financial results for ...
... Favrille, Inc. (Nasdaq:,FVRL), a biopharmaceutical company developing ... reported its financial,results for the first quarter ended ... $10.5 million, or $0.25 per share, compared to ... period in 2007., (Logo: http://www.newscom.com/cgi-bin/prnh/20080404/LAF521LOGO ), ...
... May 8 The Maryland Stem Cell,Research Commission ... in response to its three official Requests for ... Technology Development,Corporation (TEDCO) reviewed the Commission,s recommendations today ... Stem Cell Research,Fund (MSCRF) under the Maryland Stem ...
Cached Biology Technology:Pharsight Achieves $7.6 Million In Quarterly Revenue 2Pharsight Achieves $7.6 Million In Quarterly Revenue 3Pharsight Achieves $7.6 Million In Quarterly Revenue 4Pharsight Achieves $7.6 Million In Quarterly Revenue 5Pharsight Achieves $7.6 Million In Quarterly Revenue 6Pharsight Achieves $7.6 Million In Quarterly Revenue 7Pharsight Achieves $7.6 Million In Quarterly Revenue 8Pharsight Achieves $7.6 Million In Quarterly Revenue 9Pharsight Achieves $7.6 Million In Quarterly Revenue 10Pharsight Achieves $7.6 Million In Quarterly Revenue 11Pharsight Achieves $7.6 Million In Quarterly Revenue 12Favrille Reports First Quarter 2008 Financial Results 2Favrille Reports First Quarter 2008 Financial Results 3Favrille Reports First Quarter 2008 Financial Results 4Favrille Reports First Quarter 2008 Financial Results 5Favrille Reports First Quarter 2008 Financial Results 6Favrille Reports First Quarter 2008 Financial Results 7Favrille Reports First Quarter 2008 Financial Results 8Favrille Reports First Quarter 2008 Financial Results 9Maryland Stem Cell Research Commission Recommends 62 Projects for Funding 2Maryland Stem Cell Research Commission Recommends 62 Projects for Funding 3
(Date:8/11/2015)... 2015 Today, ZUK announced its Android smartphone ... as expected revenues in 2015 that relate to sales of FPC1155 ... of approximately 2,200 MSEK for 2015. Jörgen Lantto, CEO ... prominent smartphone manufacturer in China ... FPC1 155 for Z1 , ...
(Date:8/6/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ... today announced collaboration with Microsoft on biometric fingerprint ... leveraged Synaptics, deep expertise in human interface which ... Through stringent testing, Synaptics, advanced image sensing ... Precision TouchPad (PTP) specification empowering OEMs with Windows ...
(Date:8/4/2015)... -- AMRI (NASDAQ: AMRI ) today reported financial and operating results ... , Second quarter contract revenue of $ 85.2 ... Adjusted contract margins of 26 % , ... decrease in EPS from royalties in the current quarter ... "We are very pleased to present another strong financial quarter, with ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24
... in the West Australian Kimberley has been identified as ... theory on how the first land animals evolved. , ... Tim Holland were part of the research team, led ... that made the spectacular discovery by studying a 380 ...
... Many of them had narrow, pointed teeth, which were more ... how did they then grind their food? Until recently many ... they swallowed. In their muscular stomach these then acted as ... seem to be correct, as scientists at the universities of ...
... used since the 1930s to estimate the abundance of ... patrols are effective at reducing poaching of elephants, African ... in Tanzania. , "Wildlife within protected areas is ... trades, and many argue that enforcement within protected areas ...
Cached Biology News:Dinosaurs -- stones did not help with digestion 2Dinosaurs -- stones did not help with digestion 3Serengeti patrols cut poaching of buffalo, elephants, rhinos 2
... lab productivity and allows you to achieve a ... ahead beyond traditional paper-based weighing processes into a ... supported: Control ... XP, PR, SR, PG-S, PG, SG, AT, MT, ...
... enable rapid analytical to medium scale affinity ... appropriate vectors. Sufficient reagents are provided for ... protein under native or denaturing conditions. Crude ... specifically retains STag fusion proteins. After unbound ...
... STag Purification Kits enable rapid analytical to ... proteins produced from appropriate vectors. Sufficient reagents ... 1 mg target protein under native or ... S-protein Agarose, which specifically retains STag fusion ...
High affinity antibody reacting with S-100 ab heterodimer. Could be used for Western blotting application and immunoassay....
Biology Products: